Key result
Sutureless AVR in LV dysfunction linked to a ~6% absolute increase in discharge LVEF.
Why the study?
Patients with severe aortic stenosis and reduced LVEF have a poor prognosis compared with those with preserved LVEF, and the impact of sutureless Perceval aortic bioprosthesis on LVEF and outcomes in this population was evaluated.
Does sutureless aortic bioprosthesis implantation improve LVEF and clinical outcomes in patients with severe aortic stenosis and reduced LVEF?
Cohort (n=52)
Does sutureless aortic bioprosthesis implantation improve LVEF and clinical outcomes in patients with severe aortic stenosis and reduced LVEF?
Sutureless aortic valve replacement in patients with severe aortic stenosis and left ventricular dysfunction is associated with significant early and sustained improvements in LVEF and reduction in LV mass.
Objective Patients with severe aortic stenosis and reduced left ventricular ejection fraction (LVEF) have a poor prognosis compared with patients with preserved LVEF. To evaluate the impact of sutureless Perceval (LivaNova, Italy) aortic bioprosthesis on LVEF and clinical outcomes in patients with baseline left ventricular (LV) dysfunction who underwent isolated aortic valve replacement (AVR). Methods Between March 2011 and August 2017, 803 patients underwent AVR with Perceval bioprosthesis implantation. Fifty-two isolated AVR had preoperative LVEF ≤45%. Mean age of these patients was 77 ± 6 years, 24 patients were female (46%), and mean EuroSCORE II was 9.4% ± 4.8%. Perceval bioprosthesis was implanted in 9 REDO operations. In 43 patients (83%), AVR was performed in minimally invasive surgery with an upper ministernotomy ( n = 13) or right anterior minithoracotomy ( n = 30). Results One patient died in hospital. Cardiopulmonary bypass and aortic cross-clamp times were 85.5 ± 26 minutes and 55.5 ± 19 minutes, respectively. At mean follow-up of 33 ± 20 months (range: 1 to 75 months), survival was 90%, freedom from reoperation was 100%, and mean transvalvular pressure gradient was 11 ± 5 mmHg. LVEF improved from 37% ± 7% preoperatively to 43% ± 8% at discharge ( P < 0.01) and further increased to 47% ± 9% at follow-up ( P = 0.06), LV mass decreased from 149.8 ± 16.9 g/m 2 preoperatively to 115.3 ± 11.6 g/m 2 at follow-up ( P < 0.001), and moderate paravalvular leakage occurred in 1 patient without hemolysis not requiring any treatment. Conclusions AVR with sutureless aortic bioprosthesis implantation in patients with preoperative LV dysfunction demonstrated a significant immediate and early improvement in LVEF.
No takes yet. Share an insight, caveat, or question.
Concistrè et al. (2019) conducted a cohort in Severe aortic stenosis with reduced left ventricular ejection fraction (n=52). Sutureless Perceval aortic bioprosthesis implantation was evaluated on Left ventricular ejection fraction (LVEF) and clinical outcomes (p=< 0.01). Aortic valve replacement with a sutureless bioprosthesis in patients with preoperative LV dysfunction significantly improved LVEF from 37% preoperatively to 43% at discharge (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: